

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – September 12, 2018 @ 4:00pm

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. July 11, 2018 DUR Minutes – Vote
- B. July 11, 2018 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Proton Pump Inhibitor (PPI) Deprescribing Mailing Update – See Appendix B

- A. Medication Coverage Activity for July 2018
- B. Pharmacy Helpdesk Activity for July 2018
- C. Medication Coverage Activity for August 2018
- D. Pharmacy Helpdesk Activity for August 2018
- E. Proton Pump Inhibitor (PPI) Deprescribing Mailing Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Apadaz[®] [Benzhydrocodone/Acetaminophen (APAP)], Lucemyra[™] (Lofexidine), and Sublocade[™] [Buprenorphine Extended-Release (ER) Injection] – See Appendix C

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Jynarque[™] (Tolvaptan) – See Appendix D

- A. Introduction
- B. Market News and Updates
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

7. Annual Review of Breast Cancer Medications and 30-Day Notice to Prior Authorize Verzenio[™] (Abemaciclib), Ogivri[™] (Trastuzumab-dkst), and Lynparza[®] (Olaparib) – See Appendix E

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Breast Cancer Medications
- D. Prior Authorization of Breast Cancer Medications
- E. Market News and Updates
- F. Product Summaries
- G. Recommendations
- H. Utilization Details of Breast Cancer Medications

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

8. Annual Review of Sickle Cell Disease (SCD) Medications and 30-Day Notice to Prior Authorize NutreStore® (L-Glutamine) and Siklos® (Hydroxyurea) – See Appendix F

- A. Current Prior Authorization Criteria
- B. Utilization of SCD Medications
- C. Prior Authorization of SCD Medications
- D. Market News and Updates
- E. Siklos® (Hydroxyurea) Product Summary
- F. NutreStore® (L-Glutamine Powder for Oral Solution) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of SCD Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

9. Annual Review of Phenylketonuria Medications and 30-Day Notice to Prior Authorize Palynziq™ (Pegvaliase-pqpz) – See Appendix G

- A. Phenylketonuria Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Phenylketonuria Medications
- D. Prior Authorization of Phenylketonuria Medications
- E. Market News and Updates
- F. Palynziq™ (Pegvaliase-pqpz) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Phenylketonuria Medications

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

10. Annual Review of Synagis® (Palivizumab) – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization of Synagis® (Palivizumab)
- C. Prior Authorization of Synagis® (Palivizumab)
- D. Season Comparison
- E. Market News and Updates
- F. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

11. Annual Review of Fabry Disease Medications and 30-Day Notice to Prior Authorize Galafold™ (Migalastat) – See Appendix I

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Fabrazyme® (Agalsidase Beta)
- D. Prior Authorization of Fabrazyme® (Agalsidase Beta)
- E. Market News and Updates
- F. Galafold™ (Migalastat) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Fabrazyme® (Agalsidase Beta)

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

12. 30-Day Notice to Prior Authorize Qbrexza™ (Glycopyrronium) – See Appendix J

- A. Hyperhidrosis Introduction
- B. Qbrexza™ (Glycopyrronium) Product Summary
- C. Market News and Updates
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

13. Annual Review of Antihyperlipidemics and 30-Day Notice to Prior Authorize FloLipid® (Simvastatin Oral Suspension) – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Antihyperlipidemics
- C. Prior Authorization of Antihyperlipidemics
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Antihyperlipidemics

Non-Presentation; Questions Only:

14. Annual Review of Parathyroid Medications – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of Parathyroid Medications
- C. Prior Authorization of Parathyroid Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Calcimimetics and Vitamin D Analogs
- G. Utilization Details of Natpara® (Parathyroid Hormone Injection)

Non-Presentation; Questions Only:

15. Annual Review of Growth Hormone – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of Growth Hormone
- C. Prior Authorization of Growth Hormone
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Growth Hormone

Non-Presentation; Questions Only:

16. Industry News and Updates – See Appendix N

- A. Introduction
- B. News and Updates

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

17. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix O

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

18. Future Business* (Upcoming Product and Class Reviews)

- A. Targeted Immunomodulator Agents
- B. Topical Corticosteroids
- C. Constipation and Diarrhea Medications
- D. Bladder Control Medications
- E. Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Medications
- F. Skin Cancer Medications
- G. Gonadotropin-Releasing Hormone Medications
- H. Butalbital Medications

**Future business subject to change.*

19. Adjournment